Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH approps

This article was originally published in The Tan Sheet

Executive Summary

NCCAM would receive $116.2 mil. in FY 2004 funding under House Labor/HHS appropriations bill, which passed by 215-208 vote July 10. Level matches Bush Administration proposal and represents budget increase of about 3.6%, which would be smallest funding growth since center's inception (1"The Tan Sheet" Feb. 10, 2003, p. 7). NIH would be advanced $28 bil. in FY 2004, an increase of $681 mil. that matches Bush Administration's budget request...

You may also be interested in...



Washington In Brief

Burton gets subcommittee chair: Former House Government Reform Committee Chair Dan Burton (R-Ind.) named to oversee newly created Subcommittee on Wellness & Human Rights, Committee Chair Tom Davis (R-Va.) announces Jan. 31. Subcommittee will address issues concerning public health policy, human rights and family health, according to Davis' office. Votes to confirm the subcommittee and chairman appointment will be taken when the full Government Reform Committee convenes, possibly the week of Feb. 10. In his new position, Burton likely will revisit dietary supplement-related issues, which were the subject of frequent hearings during his tenure as full committee chair...

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS095688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel